Edition:
United States

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

1.65USD
24 May 2017
Change (% chg)

$0.08 (+4.76%)
Prev Close
$1.58
Open
$1.60
Day's High
$1.65
Day's Low
$1.58
Volume
120,167
Avg. Vol
130,281
52-wk High
$8.35
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Sorrento Therapeutics says selling stockholders may sell up to 797,081 shares of common stock of co - SEC Filing
Thursday, 4 May 2017 05:53pm EDT 

May 4 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics Inc - Selling stockholders may sell up to 797,081 shares of common stock of co - SEC Filing.  Full Article

Sorrento announces proposed public offering of common stock
Wednesday, 12 Apr 2017 04:12pm EDT 

Sorrento Therapeutics Inc :Sorrento announces proposed public offering of common stock.  Full Article

Sorrento therapeutics anti-CEA car-T demonstrates promising clinical activity and safety in phase IB clinical trial
Monday, 3 Apr 2017 01:25pm EDT 

Sorrento Therapeutics Inc : Sorrento therapeutics anti-cea car-t demonstrates promising clinical activity and safety in phase IB clinical trial . In addition, from a safety standpoint, HITM-SIR protocol was well tolerated . There were no grade 4 or grade 5 events related to anti-cea car-t, sirt, or combination . All colitis episodes resolved with il-2 dose reductions .Sorrento - "anti-cea car-t hai may represent a safe & well tolerated component of novel multi-modality regimens capable of meaningful disease control.".  Full Article

Sorrento Therapeutics- co, units, Hercules enters into a fourth amendment to a loan and security agreement
Friday, 24 Mar 2017 06:11am EDT 

Sorrento Therapeutics Inc : Sorrento Therapeutics- on March 23, 2017, co, units, Hercules entered into a fourth amendment to that certain loan and security agreement . Sorrento Therapeutics Inc - loan agreement provides for a term loan of up to $75.0 million, subject to funding in multiple tranches . Sorrento Therapeutics Inc - under amendment, hercules reduced minimum amount of unrestricted cash that company must maintain under loan agreement . Sorrento Therapeutics-as per amendment, co to repay to hercules, without repayment penalty, $20.0 million of outstanding principal, unpaid interest accrued thereon . Sorrento Therapeutics Inc - under amendment, parties agreed to change date by which company must achieve a fundraising milestone .Sorrento Therapeutics Inc - in accordance with amendment, on March 23, 2017, company repaid repayment amount.  Full Article

Sorrento, Wildcat announce resolution
Monday, 20 Mar 2017 08:00am EDT 

Sorrento Therapeutics Inc : Sorrento and Wildcat announce resolution . Sorrento Therapeutics - reached mutual resolution with wildcat capital with respect to Wildcat's seeking of inspection of co's private placement . Sorrento Therapeutics - co and Wildcat have engaged in talks relating to steps needed to undertake in order to increase Sorrento's shareholder value . Sorrento Therapeutics Inc - as part of its core immuno-oncology business, sorrento is preparing to file an IND for at least one car-T phase I study .Sorrento Therapeutics Inc - Sorrento makes no admission of liability or wrongdoing in connection with Wildcat's inspection demand.  Full Article

Sorrento Therapeutics files for non-timely 10-K
Thursday, 16 Mar 2017 06:19am EDT 

Sorrento Therapeutics Inc : Sorrento Therapeutics Inc files for non-timely 10-K - SEC filing . Sorrento Therapeutics - as a result of acquisitions, other one-time items occurring late in Q4 2016, it is unable to file form 10-K within prescribed time period .Sorrento Therapeutics - will require additional time to ensure adequate disclosure of certain information required to be included in the form 10-K.  Full Article

Sorrento Therapeutics unit says key endpoints met in EU Pivotal Bioequivalence Clinical Study for ZTlido
Monday, 9 Jan 2017 09:00am EST 

Sorrento Therapeutics Inc - : Sorrento subsidiary, Scilex Pharmaceuticals, announces key endpoints met in the European Union Pivotal Bioequivalence Clinical Study for its lead product, ZTlido™ .Sorrento Therapeutics Inc- Marketing Authorization Application is expected to be filed in mid-2017 for ZTlido.  Full Article

Sorrento Therapeutics' study for ztlido meets primary endpoint
Monday, 5 Dec 2016 07:00am EST 

Sorrento Therapeutics Inc : Sorrento Therapeutics Inc - study for lead investigational product, ztlido has met a primary endpoint . Sorrento subsidiary, Scilex Pharmaceuticals announces key endpoints met in pivotal bioequivalence clinical study for its lead product, ztlido .Scilex Pharmaceuticals Inc - full data will be resubmitted to FDA as part of 505(B)(2) new drug application (NDA) in mid-2017.  Full Article

Sorrento Therapeutics files for resale of up to 1.2 mln shares of co's common stock by selling stockholders
Friday, 2 Dec 2016 05:38pm EST 

Sorrento Therapeutics Inc :Sorrento Therapeutics files for resale of up to 1.2 million shares of co's common stock by selling stockholders - SEC filing.  Full Article

Scintilla Pharma, a unit of Sorrento Therapeutics, to buy Semnur Pharma
Monday, 15 Aug 2016 06:34pm EDT 

Sorrento Therapeutics : Scintilla will pay semnur an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of sorrento . Scintilla pharmaceuticals,a subsidiary of sorrento therapeutics, inc., to acquire semnur pharmaceuticals .Additional cash consideration of up to $140 million may be paid by scintilla to semnur upon achievement of certain milestones.  Full Article

More From Around the Web

BRIEF-Sorrento Therapeutics files for non-timely 10-Q - SEC Filing

* Sorrento Therapeutics says late filing on form 10-Q because it needs additional time to complete final review of financial statements and other disclosures